接受免疫检查点抑制剂治疗的晚期癌症实体器官移植受者的结局:系统综述与个体参与者数据Meta分析
该系统综述与个体参与者数据Meta分析纳入128项研究、343例接受免疫检查点抑制剂(ICI)治疗的实体器官移植受者(SOTR)。3年内癌症相关死亡率为52.8%,1年急性排斥反应发生率为36.2%,1年移植物丢失率为18.4%,1年客观缓解率为31.6%。皮肤鳞状细胞癌(cSCC)的缓解率高于黑色素瘤和其他实体器官癌。黑色素瘤和其他实体器官癌的癌症相关死亡风险高于cSCC。维持使用类固醇和mTOR抑制剂与较低的排斥风险相关。
要点
- SOTR接受ICI后3年内癌症相关死亡率为52.8%(95%CI 43.9%-61.6%)。
- 1年急性排斥反应发生率为36.2%(95%CI 30.7%-41.7%),1年移植物丢失率为18.4%(95%CI 13.7%-23.1%)。
- 1年客观缓解率为31.6%(95%CI 25.0%-37.7%),cSCC为61.0%,黑色素瘤为48.5%,其他实体器官癌为26.9%。
核心结论
- 在接受ICI治疗的SOTR中,癌症结局因癌症类型而异,cSCC患者获得缓解的概率高于其他癌症。
- 在ICI治疗期间同时使用mTOR抑制剂和类固醇可能降低急性同种异体移植物排斥反应的风险。
研究设计与样本
- 系统综述与个体参与者数据Meta分析,检索MEDLINE、Embase、ClinicalTrials.gov、澳大利亚新西兰临床试验注册库和世界卫生组织国际临床试验注册平台,从建库至2024年6月,无语言限制。
- 纳入病例报告和系列、观察性研究和临床试验,描述SOTR中晚期癌症使用ICI的治疗。
- 共纳入140项研究中的128项研究,涉及343例接受ICI治疗的SOTR。
- 使用单阶段随机效应模型提取和合成个体参与者数据。
- 主要结局为癌症相关死亡时间;次要结局包括从ICI启动到首次排斥的时间以及根据实体瘤疗效评价标准1.1版的癌症缓解。
主要发现
- 大多数参与者为男性(76.9%)、肾移植受者(70.9%),中位(IQR)年龄为63岁(14-88岁),接受程序性细胞死亡蛋白-1抑制剂治疗(72.9%)。
- 在ICI启动后3年内,52.8%(95%CI 43.9%-61.6%)死于癌症。
- 1年时急性排斥反应发生率为36.2%(95%CI 30.7%-41.7%),1年时18.4%(95%CI 13.7%-23.1%)经历移植物丢失。
- 1年时客观缓解率为31.6%(95%CI 25.0%-37.7%),其中cSCC为61.0%(95%CI 45.5%-76.4%),黑色素瘤为48.5%(95%CI 26.8%-70.3%),其他实体器官癌为26.9%(95%CI 14.5%-39.3%)。
- 黑色素瘤(HR 2.29;95%CI 1.31-3.99)和其他实体器官癌(HR 2.84;95%CI 1.70-4.74)的移植受者癌症相关死亡风险高于cSCC。
关键数值与推荐
- 客观缓解根据实体瘤疗效评价标准1.1版评估。
- 癌症相关死亡时间为主要结局,采用校正Cox比例风险回归模型进行时间-事件分析。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: Immune checkpoint inhibitors (ICIs) have improved overall survival in patients with advanced-stage cancers. However, data on their efficacy and safety in solid organ transplant recipients (SOTRs) are limited. OBJECTIVE: To examine cancer-specific and patient survival among SOTRs with advanced-stage cancer receiving ICIs and identify factors associated with patient and graft outcomes. DATA SOURCES: Electronic databases and clinical registries, including MEDLINE, Embase, ClinicalTrials.gov, Australia New Zealand clinical trials registry, and the World Health Organization International Clinical Trials Registry Platform, were searched from inception to June 2024 without language restriction. STUDY SELECTION: Case reports and series, observational studies, and clinical trials that described the treatment of advanced-stage cancers using ICIs in SOTRs were included. DATA EXTRACTION AND SYNTHESIS: Individual participant data were extracted and synthesized using a single-stage random-effect model. MAIN OUTCOMES AND MEASURES: Time to cancer-related death was the primary outcome. The main secondary outcomes included time from ICI initiation to first rejection and cancer response according to Response Evaluation Criteria in Solid Tumors 1.1 criteria. Adjusted Cox proportional hazards regression models were conducted for time-to-event analyses. RESULTS: Of 140 studies, 128 studies involving 343 SOTRs treated with ICI were included. Most participants were male (76.9%), kidney transplant recipients (70.9%), with a median (IQR) age of 63 years (14-88 years), and treated with programmed cell death protein-1 inhibitors (72.9%). Within 3 years of ICI initiation, 52.8% (95% CI, 43.9%-61.6%) died of cancers. Acute rejection occurred in 36.2% (95% CI, 30.7%-41.7%) at 1 year, and 18.4% (95% CI, 13.7%-23.1%) experienced graft loss at 1 year. Objective response at 1 year was 31.6% (95% CI, 25.0%-37.7%), with a higher response observed in patients with cutaneous squamous cell carcinoma (cSCC) (61.0% [95% CI, 45.5%-76.4%]) than melanoma (48.5% [95% CI, 26.8%-70.3%]), and other solid organ cancers (26.9% [95% CI, 14.5%-39.3%]). Transplant recipients with melanoma (hazard ratio [HR], 2.29; 95% CI, 1.31-3.99) and solid organ cancers (HR, 2.84; 95% CI, 1.70-4.74) experienced higher rates of cancer-related deaths than those with cSCC. Recipients with melanoma have a higher risk of acute rejection (HR, 2.88; 95% CI, 1.69-4.90) than cSCC. Maintenance with steroids and mammalian target of rapamycin inhibitors (mTORIs) was associated with a lower risk of rejection compared with other immunosuppressive agents (HR, 0.30; 95% CI, 0.14-0.63). CONCLUSIONS AND RELEVANCE: In this study, cancer outcomes in SOTRs receiving ICIs varied by cancer type, with a higher probability of achieving response among those with cSCC than other cancers. Concurrent use of mTORIs and steroids during ICI therapy may reduce the risk of acute allograft rejection.
引用
- Saleem N, Wang J, Rejuso A, et al. Outcomes of Solid Organ Transplant Recipients With Advanced Cancers Receiving Immune Checkpoint Inhibitors: A Systematic Review and Individual Participant Data Meta-Analysis. JAMA Oncol. 2025. PMID: 40545616. doi:10.1001/jamaoncol.2025.2374
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。